Sanofi (EURONEXT:
SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type
9), met its primary efficacy endpoint. The mean low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) reduction from baseline to week 24, the primary efficacy endpoint of the study, was significantly greater in patients randomized to alirocumab,
as compared to patients randomized to ezetimibe (47.2% vs.
15.6%, p<0 .0001="" 70="" 75="" a="" achieve="" alirocumab="" an="" deciliter="" did="" dl="" dose="" employed="" for="" in="" increase="" initial="" ldl-c="" level="" low="" majority="" mg="" milligrams="" nbsp="" not="" of="" on="" patients="" remained="" span="" the="" trial="" up-titration="" which="" who="">
“We are excited with the findings from the first Phase 3 trial with alirocumab. While the majority of our clinical program is investigating alirocumab in combination with lipid-lowering therapies,
these monotherapy results are encouraging,” said Jay Edelberg M.D., Ph.D., Head of the PCSK9 Development and Launch Unit, Sanofi Group. “As in this trial, several of our Phase 3 studies will utilize an up-titration approach, the aim of which is to bring patients
to goal with the lowest effective dose of anti-PCSK9 antibody. We look forward to results from the remaining Phase 3 trials, which are investigating alirocumab in a variety of patient populations, combinations with different background therapies, and dosing
regimens.”
The percentage of patients who reported treatment emergent adverse events was 78.4% in the ezetimibe group and 69.2% in the alirocumab group. The most common class of adverse events was infections
(39.2% with ezetimibe vs. 42.3% with alirocumab), which included nasopharyngitis, influenza, and upper respiratory tract infection. Injection-site reactions occurred in less than 2% of patients in both groups. Muscle-related adverse events occurred in 3.9%
of patients treated with ezetimibe and 3.8% of patients treated with alirocumab.
ODYSSEY MONO is the first study to report data from the 12 Phase 3 trials that have
been initiated so far as part of the more than 23,000 patient ODYSSEY clinical trial program.
“There are still millions of people around the globe who have poorly controlled LDL-C,” said George D. Yancopoulos, M.D., Ph. D., Chief Scientific Officer of Regeneron and President of Regeneron
Laboratories. “Three years ago, our Phase 1 trials generated the first clinical evidence that blocking PCSK9 could markedly lower cholesterol levels in humans. Today, it is very gratifying to be able to report the first Phase 3 data for this promising potential
new class of lipid-lowering agents. It is important to point out that
these are just the first of a large amount of data yet to come from our extensive ODYSSEY Phase
3 program.”
ODYSSEY MONO (N=103) was a randomized, double-blind, active-controlled, parallel-group study to evaluate the efficacy and safety of alirocumab over 24 weeks in patients with primary hypercholesterolemia
and moderate cardiovascular risk. Patients in the trial were randomized to receive monotherapy with either ezetimibe 10 mg, an alternative to statin therapy, or alirocumab. Alirocumab was self-administered initially at
its low dose of 75 mg every two weeks, and was up-titrated at week 12 to 150 mg if the LDL-C measurement at week 8
was above 70 mg/dL. The majority of alirocumab patients in the trial remained on the initial low dose of alirocumab because they achieved LDL-C below
70 mg/dL at week 8.
Alirocumab was self-administered subcutaneously using a single 1 milliliter (mL) auto-injector.
Detailed results from the ODYSSEY MONO study will be presented at an upcoming medical conference in 2014.
No comments:
Post a Comment